Zusammenfassung
Vor etwa vierzig Jahren, als erstmals klassische Neuroleptika zur Verfügung standen, machten sich die Psychiater große Hoffnungen, daß die Geißel der Schizophrenie aus der Welt geschafft werden könnte, um so mehr, als die Entwicklung der Antibiotika nahezu zu einer totalen Eliminierung einer Reihe von Infektionskrankheiten führte. Nun, vor dem nüchternen und realistischen Hintergrund von fast vierzig Jahren neuroleptischer Therapie, erkennen wir, daß die Schizophrenie uns noch immer sehr beschäftigen muß. Neuroleptika haben einen großen Teil dazu beigetragen, die Symptome der Psychose zu reduzieren und es vielen Patienten zu ermöglichen, in der Gesellschaft zu leben. Sie haben uns jedoch eine Patientengruppe hinterlassen, die unter entstellenden Dyskinesien, andauernder Psychose und ernstem sozialen Unvermögen leiden. Wir erkennen jetzt, daß der therapieresistente Patient eine bedeutende Herausforderung an die Neurophar-makologie und die Psychiatrie darstellt.
Für die Übertragung aus dem Englischen verantwortlich: Dr. F. Kulhanek, München, und Oberärztin Dr. R. Neumann, Innsbruck.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 1982a; 39: 784–788.
Andreasen NC. Negative vs. positive schizophrenia: definition and validation. Arch Gen Psychiatry 1982b; 39: 789–794.
Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, Iowa: The University of Iowa, 1983.
Andreasen NC. The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, Iowa: The University of Iowa, 1984.
Andreasen NC. Positive vs. negative schizophrenia: a critical evaluation. Schizophr Bull 1985; 11: 380–389.
Andreasen NC. Brain imaging: applications in psychiatry. Science 1988; 239: 1381–1388.
Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988; 1: 179–186.
Carpenter WT, Heinrichs DW, Alphs LD. Treatment of negative symptoms. Schizophr Bull 1985; 11: 440–452.
Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antipsychotic drugs. Science 1976; 192: 481–483.
Crow TJ. Molecular pathology of schizophrenia: More than one disease process? BMJ 1980; 280: 66 – 68.
Dieterle DM, Albus MI, Eben E, Ackenheil M, Rockstroh W. Preliminary experiences and results with the Munich version of the Andreasen Scale. Pharmacopsychiatry 1986; 19: 96–100.
Farde L, Wiesel FA, Hall H, Halldin C, Stone-Elander S, et al. No D2 receptor increase in PET study of schizophrenia. Arch Gen Psychiatry 1987; 44: 671–672.
Farde L, Wiesel FA, Halldin C, Sedvall G. Central D2 dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988; 45: 71–76.
Friedhoff AJ. Dopamine as a mediator of a central stabilizing system: comments on the current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988; 1: 189–191.
Humbert M, Salvador L, Segui J, Obiols J, Obiols JE. Estudio interfiabilidad version espanola evaluacion de sintomas positivos y negativos. Rev Dpto Psiquiatria Facultad de Med, University of Barcelona, 1986; 13: 28–36.
Kane J, Honigfeld G, Singer J, Meltzer H, and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–796.
Meltzer HY. New insights into schizophrenia through atypical antipsychotic drugs: comments on „The Current Status of the Dopamine Hypothesis of Schizophrenia“. Neuropsychopharmacology 1988; 1: 193–196.
Moscarelli M, Maffei C, Cesana BM, Boato P, Farma T, et al. An international perspective on assessment of negative and positive symptoms in schizophrenia. Am J Psychiatry 1987; 144: 1595 – 1598.
Ohta T, Okazaki Y, Anzei N. Reliability of the Japanese version of the Scale for the Assessment of Negative Symptoms (SANS). Jpn J Psychiatry Neurol 1984; 13: 999–1010.
Overall J, Gorham D. Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799–812.
Phillips M. Scale for the Assessment of Negative Symptoms and Scale for the Assessment of Positive Symptoms, Chinese version. National Center for Psychiatric Training, Shashi Psychiatric Hospital, Shashi Hubei, People’s Republic of China. Personal Communication, 1987, 1988.
Sedvall G, Farde L, Persson A, Wiesel FA. Imaging of neurotransmitter receptors in the living human brain. Arch Gen Psychiatry 1986; 43: 995–1005.
Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717–719.
Seeman P, Ulpian C, Bergeron C, Riederer P, Jellinger K, et al. Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science 1984; 225: 728–731.
Snyder SH. Psychotogenic drugs as models for schizophrenia: comments on „The Current Status of the Dopamine Hypothesis of Schizophrenia.“ Neuropsychopharmacology 1988; 1: 197–199.
Weinberger DR, Bigelow LB, Kleinman JE, Klein ST, Aosenblatt JD, et al. Cerebral ventricular enlargement in chronic schizophrenia: an association with poor response to therapy. Arch Gen Psychiatry 1980; 37: 11–13.
Wong DF, Wagner HN, Tune LE, Dannals RF, Pearlson GD, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986; 234:1558–1562.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Friedr. Vieweg & Sohn Verlagsgesellschaft mbH, Braunschweig/Wiesbaden
About this chapter
Cite this chapter
Andreasen, N.C. (1993). Die Behandlung des therapieresistenten schizophrenen Patienten. In: Hinterhuber, H., Fleischhacker, W.W., Kulhanek, F., Neumann, R. (eds) Prädiktoren und Therapieresistenz in der Psychiatrie. Vieweg+Teubner Verlag. https://doi.org/10.1007/978-3-322-86114-6_9
Download citation
DOI: https://doi.org/10.1007/978-3-322-86114-6_9
Publisher Name: Vieweg+Teubner Verlag
Print ISBN: 978-3-528-07857-7
Online ISBN: 978-3-322-86114-6
eBook Packages: Springer Book Archive